Clinical Trial Update: Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating IDX719 in participants with normal and impaired hepatic function to support dosing considerations in chronic hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX719 (NS5A inhibitor)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED